Physician profile
Charles L Brown
NPI 1851307755
$40,699.43
in general payments reported to CMS, 2019-2025
28 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $541 · 2021: $1,186 · 2022: $1,141 · 2023: $979 · 2024: $1,075 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34,504.28 | 2019-2024 | Avvigo Guidance System, Watchman Flx |
| Medtronic, INC. | $1,085.32 | 2021-2023 | Onyx Frontier, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $986.41 | 2019-2025 | |
| Medtronic Vascular, INC. | $628.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $564.45 | 2019-2024 | Xarelto |
| Cvrx, INC. | $405.86 | 2024-2025 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $283.75 | 2021 | |
| Biotronik INC. | $259.69 | 2023-2024 | Orsiro Mission, Pk Papyrus |
| Abiomed | $256.44 | 2019-2024 | Impella |
| Amgen INC. | $250.76 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $206.85 | 2020-2024 | Andexxa |
| Shockwave Medical, INC | $192.03 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $189.95 | 2020-2025 | |
| Endologix LLC | $153.86 | 2024 | Torus Stent Graft System, Endocross Device |
| E.R. Squibb & Sons, L.L.C. | $148.29 | 2021-2025 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $121.72 | 2021-2022 | |
| Acist Medical Systems, INC. | $81.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.22 | 2021-2022 | |
| Amarin Pharma, INC. | $56.31 | 2019-2020 | |
| Heartflow, INC. | $42.96 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.16 | 2022 | |
| Esperion Therapeutics, INC. | $37.71 | 2021-2025 | Nexletol |
| Angiodynamics, INC. | $37.06 | 2023 | Alphavac |
| Kestra Medical Technology Services, INC. | $35.68 | 2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $22.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.77 | 2023 | Rexulti |
| Baxter Healthcare | $16.39 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Allergan, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.